Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 1999

View Archived Issues

Fluvastatin lowers LDL, raises HDL cholesterol

Genzyme Transgenics: Q4 and year-end 1998 highlights

Nabi: Q4 and year-end 1998 highlights

Millennium delivers seventh antibacterial drug target to Wyeth-Ayerst

Procept and Pacific Pharmaceuticals merge, pipeline updated

Genetronics receives CE Mark approval for MedPulser solid tumor treatment

Texas Biotechnology resubmits Novastan NDA

American Home Products patents selective, orally active, nonpeptide V2 agonists

Recordati presents new series for lower urinary tract dysfunction

Anti-MRSA cephems developed at Bristol-Myers Squibb

Integrin receptor antagonists disclosed by SB

Toyama searches for effective and safe quinolones

Kyowa Hakko and Cor select development candidates for inhibiting PDGF receptor phosphorylation

Favorable safety and PK/PD profiles reported for CFC-222

ACS highlights: 3-D progresses in development of new class of thrombin inhibitors

Dual dopamine D1/D5 antagonist blocks the rewarding effects of cocaine in humans

High-affinity RARalpha receptor agonists reported by Eisai at ACS meeting

Allos presents phase Ib results of RSR-13 in patients with angina

DuPont presents 4-aminoquinazoline cyclin-dependent kinase inhibitors

Pharmacokinetics of AMP-579 are affected by body weight but not by renal function

Ariad receives broader patent coverage for its ARGENT and Dimerizer Drugs technologies

Antiarrhythmic efficacy of Na+/Ca2+ exchange inhibitor demonstrated in preclinical models

Patent issued to GenVec covering gene delivery systems targeting specific tissues

Conformationally restricted CRF1 antagonists developed at Merck & Co.

Preclinical activity of JTH-601, a novel alpha-adrenoceptor antagonist from Japan Tobacco

Highly potent and selective sst2 receptor agonist: discovery and synthesis discussed at ACS meeting

ACS highlights: novel guanylureas as NPY Y1 antagonists presented by Alanex

Merck reveals progress in obesity/diabetes program at ACS meeting

New series of benzimidazole ribosides for HCMV infection discovered at Glaxo Wellcome

Highlights from ACS: potent and selective alpha2-blocker presented by Pierre Fabre

ACS presentation for LY-377604, Lilly's beta3-agonist for metabolic syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...